Clinical trial Recruiting at 1 site Observational Ages 18 and up

Using C-reactive protein to albumin ratio to predict heart events in acute coronary syndrome

Official title: Prediction of Acute Coronary Syndrome In-hospital Major Adverse Cardiovascular Events by High Sensitivity C- Reactive Protein to Albumin Ratio

Run by Sohag University · NCT06673381 · Data updated 2026-11-12

This study is testing if a blood test measuring the C-reactive protein to albumin ratio can help predict serious heart problems in patients with acute coronary syndrome while they are in the hospital.

More Acute Coronary Syndrome trials

Quick facts

Study typeObservational
Ages18 Years and up
SexAll
Enrollment240 (estimated)
SponsorSohag University
Academic / other
Locations1 site (Sohag)
StatusRecruiting
StartedNovember 1, 2024
Main results expectedNovember 1, 2024
Study endsOctober 1, 2025
Registry record updatedNovember 4, 2024
Trial IDNCT06673381 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults aged 18 and older diagnosed with acute coronary syndrome who are not candidates for primary percutaneous coronary intervention.

Probably not a fit

Patients under 18, those with severe chronic conditions, or recent infections may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study assesses the predictive value of the high sensitive C-reactive protein to albumin ratio (hs-CAR) for in-hospital short-term major adverse cardiac events (MACEs) in patients with acute coronary syndrome (ACS). Conducted at the coronary care unit of Sohag University Hospital, the study includes patients diagnosed with ACS based on established guidelines. Blood samples are collected upon admission to measure hs-CRP and serum albumin levels, allowing for the calculation of hs-CAR and classification of patients into high and low hs-CAR groups. The primary endpoint is the occurrence of in-hospital MACEs, which include serious cardiac complications.

Why it matters

Potential benefit: If successful, this study could improve the prediction of serious cardiac events in ACS patients, potentially leading to better management and outcomes.

How similar studies have gone: While the specific approach of using hs-CAR in this context may be novel, similar studies have explored biomarkers for predicting cardiac events with varying degrees of success.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* All patients aged 18 Year or older presented by ACS not candidet for primary percutaneus coronary intervention ( PCI ) .

Exclusion Criteria:

* • Patients aged \< 18 years old

  * Patients who have eGFR \<60 ml/kg /m2
  * Patients who have malignancies
  * Patients who have chronic heart failure (NYHA class \>II)
  * Pateints who have chronic liver disease
  * Patients who have nephrotic syndrome
  * Patients who have acute cerebrovascular stroke
  * Pregnant women
  * Patients who have recent infection

Where it's running

  • Sohag faculty of medicine
    Sohag, Egypt
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.